Nestle Pays $2 Billion to Secure Aimmune’s Allergy Treatment

Vevey, Switzerland, August 31 2020 (CNBC) — Nestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business. Known for its KitKat chocolate bars and Nescafe instant coffee, Nestle set up Nestle Health Science (NHS) in 2011 to open up a new area of business between food and pharma.

What do you think?

Written by hsandm

Former SVP and President for Walmart Health Pivots to Modernize the Testing Industry

Danaher Appoints Rainer M. Blair as President and CEO